Cover Image
市場調查報告書

化療誘發性嗜中性白血球低下症:開發平台分析

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245982
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性嗜中性白血球低下症:開發平台分析 Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 104 Pages
簡介

所謂化療誘發性嗜中性白血球低下症是癌症治療最常見的副作用。常見的症狀有重度疲勞、虛弱、焦慮症、能量不足、呼吸急促、頭痛、臉色極差、心搏過速、胸口疼痛、暈眩、腹痛等。致病危險因子有年齡、併發症等。

本報告提供化療誘發性嗜中性白血球低下症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

化療誘發性嗜中性白血球低下症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Apotex Inc.
  • Biogenomics Limited
  • Bolder Biotechnology, Inc.
  • Cellerant Therapeutics, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Cinfa Biotech S.L.
  • Dr. Reddy's Laboratories Limited
  • Generon (Shanghai) Corporation Ltd.
  • Genexine, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Myelo Therapeutics GmbH
  • Octapharma AG
  • Pfenex Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Reliance Life Sciences Pvt. Ltd.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • UAB Profarma
  • USV Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BBT-007
  • BBT-015
  • BBT-018
  • 化療誘發性嗜中性白血球低下症細胞療法
  • EC-18
  • eflapegrastim
  • F-627
  • filgrastim
  • GW-003
  • GXG-3
  • HSA-GCSF
  • Myelo-001
  • pegfilgrastim
  • romyelocel-L
  • TXA-302
  • WBI-2100
  • 開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8316IDB

Summary

Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
  • The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Neutropenia Overview
    • Therapeutics Development
  • Pipeline Products for Chemotherapy Induced Neutropenia - Overview
  • Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis
  • Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies
  • Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes
  • Chemotherapy Induced Neutropenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Chemotherapy Induced Neutropenia - Products under Development by Companies
  • Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes
  • Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
    • Apotex Inc.
    • Biocon Limited
    • Biogenomics Limited
    • Bolder Biotechnology, Inc.
    • Cellerant Therapeutics, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • Cinfa Biotech S.L.
    • Dr. Reddy's Laboratories Limited
    • Gene Techno Science Co., Ltd.
    • Generon (Shanghai) Corporation Ltd.
    • Genexine, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Myelo Therapeutics GmbH
    • Octapharma AG
    • Pfenex Inc.
    • Pfizer Inc.
    • Reliance Life Sciences Pvt. Ltd.
    • Richter Gedeon Nyrt.
    • Sandoz International GmbH
    • USV Limited
  • Chemotherapy Induced Neutropenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BBT-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eflapegrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-627 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXG-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSA-GCSF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myelo-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romyelocel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WBI-2100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBT-018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eflapegrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-627 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXG-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSA-GCSF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myelo-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romyelocel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WBI-2100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Neutropenia - Dormant Projects
  • Chemotherapy Induced Neutropenia - Discontinued Products
  • Chemotherapy Induced Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
      • Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco
      • Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm
      • May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia
      • Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia
      • Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China
      • May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel
      • Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients
      • Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology
      • Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia
      • Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants
      • Sep 09, 2010: Generon Submits Investigational New Drug Application For F-627 To SFDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2016
  • Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Biocon Limited, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
  • Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chemotherapy Induced Neutropenia - Dormant Projects, H2 2016
  • Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2016
  • Chemotherapy Induced Neutropenia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2016
  • Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top